http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0745609-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2891c73439a69e8f329fcb14a5cd30a0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_506ab36207e77a8c2e0343d7b2ee7b59 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16063 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-155 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-21 |
| filingDate | 1996-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f1458326d03521d581284919c719f29a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_69062c00d18886012d5374bd656b21bd http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6b1cca3c6db597c0eca192fa702142cb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_03f55e6d2bc1a995a8ca63372449ca5d |
| publicationDate | 1996-12-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-0745609-A2 |
| titleOfInvention | Vaccines for prophylaxis against HIV infections and/or for AIDS therapy and process for preparing them |
| abstract | Kultivierung von HIV in einem Kulturmedium, das als Phosphorquelle das radioaktive Phosphorisotop 32 15 P enthält; Isolierung und Abtrennung der kultivierten HIV-Partikel aus dem Kulturmedium unter solchen Bedingungen, die wenigstens 50 % oder mehr des viralen gpl20-Antigens erhalten; und Aufbewahrung der so gebildeten und isolierten HIV-Partikel, deren RNA wenigstens eine Phosphorsäure-Di-Estergruppe enthält, deren Phosphorspezies aus 32 15 P besteht für einen Zeitraum von mehr als zwei Monate bei einer Temperatur von minus 70°C oder unterhalb minus 70°C. A vaccine for the prophylaxis against HIV infection and / or for the therapy of AIDS has a content of inactivated HIV particles. The inactivated HIV particles are available from: Cultivation of HIV in a culture medium that is the source of phosphorus, the radioactive phosphorus isotope 32 15 P contains; Isolating and separating the cultured HIV particles from the culture medium under such conditions that receive at least 50% or more of the gpl20 viral antigen; and Storage of the thus formed and isolated HIV particles, the RNA of which contains at least one phosphoric acid di-ester group, the phosphorus species of 32 15 P exists for a period of more than two months at a temperature of minus 70 ° C or below minus 70 ° C. n n n Preferably, each individual HIV genome is said to be at least about 1 to 4 radioactive 32 15 P-isotopes.n n n A method for producing the vaccine provides, in addition to the above method steps, the further step of making up the inactivated HIV genome obtained after long-term low-temperature storage into an applicable vaccine. |
| priorityDate | 1995-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 49.